Skip to main content

Catalyst Calendar

Mon, Sep 14, 2026

1 updates

7:00 AM

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Trial Results • Phase 1Topline data release Mon, Sep 14, 2026, 7:00 AM EDTcorbuspharma.com

Fri, Sep 11, 2026

1 updates

4:01 PM

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

Results Call • Phase 1Results call Mon, Sep 14, 2026, 8:00 AM EDTcorbuspharma.com

Mon, Aug 17, 2026

1 updates

10:00 AM

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

corbuspharma.com

Thu, Aug 6, 2026

1 updates

8:00 AM

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

Trial Results • Phase 1CANYON-1 topline data readout Tue, Sep 1, 2026, 8:00 AM EDTcorbuspharma.com

Tue, Aug 4, 2026

1 updates

8:30 AM

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Enrollment • Phase 1corbuspharma.com

Tue, Jul 28, 2026

1 updates

8:00 AM

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

corbuspharma.com

Mon, Jul 6, 2026

1 updates

8:00 AM

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

corbuspharma.com